Choong-wae, Kaken enter into exclusive agreement for marketing of butenafine hydrochloride cream
Published: 2009-04-15 06:56:00
Updated: 2009-04-15 06:56:00
Choong-wae Shinyak, an affiliated company of Choongp-wae Holdings and Kaken Pharmaceutical Co. announced on April 13 that they have concluded a basic agreement on the exclusive marketing in Korea by Choong-wae of topical butenafine hydrochloride cream, a new benzylamine derivative
Butenafine i...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
